Related Experiment Videos
Pharmacokinetic interaction studies between felbamate and vigabatrin
P Reidenberg1, P Glue, C Banfield
1Department of Clinical Pharmacology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
British Journal of Clinical Pharmacology
|August 1, 1995
Summary
This study found that co-administering felbamate and vigabatrin does not cause clinically significant pharmacokinetic interactions. The observed changes in vigabatrin and felbamate levels were minor, suggesting they can be used together safely.
Area of Science:
- Pharmacology
- Clinical Pharmacology
- Drug Interactions
Background:
- Felbamate and vigabatrin are antiepileptic drugs.
- Potential pharmacokinetic interactions between these drugs require investigation.
Purpose of the Study:
- To evaluate pharmacokinetic interactions between felbamate and vigabatrin in healthy male volunteers.
- To determine if co-administration affects drug concentrations and elimination.
Main Methods:
- Two randomized, double-blind, placebo-controlled, crossover studies were conducted.
- Subjects received either vigabatrin with felbamate/placebo or felbamate with vigabatrin/placebo.
- Pharmacokinetic parameters were assessed via blood and urine sample analysis.
Main Results:
- Co-administration of felbamate and vigabatrin resulted in minor, statistically significant increases in S(+)-vigabatrin AUC and urinary excretion.
- Pharmacokinetic parameters for R(-)-vigabatrin and felbamate remained similar with or without the co-administered drug.
- No clinically relevant pharmacokinetic interactions were observed.
Conclusions:
- Felbamate and vigabatrin do not exhibit clinically significant pharmacokinetic interactions in humans.
- The observed minor changes are unlikely to impact therapeutic efficacy or safety.
- These findings support the potential for concurrent use of these antiepileptic agents.